FDA grants priority review to Enhertu for high-risk HER2-positive breast cancer
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
Indomo’s ClearPen system combines a proprietary self-injection device and microneedle with a modernized triamcinolone acetonide formulation
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Germany will be the first launch market
The hospitals house over 25 super-speciality centres and Centres of Excellence in Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management
The first of four planned modules at the new plant is expected to come online by summer 2026
Huwel’s diagnostic solutions leverage open RT-PCR system
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients
Subscribe To Our Newsletter & Stay Updated